Cingulate Inc. Form 8-K Summary
Business Context and Reporting Period
Cingulate Inc. (CING), a Delaware corporation, filed this Current Report on Form 8-K on March 4, 2025. The Company is an emerging growth company developing CTx-1301 (dexmethylphenidate), a novel, investigational once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only quantitative metric provided is the share count: 3,647,655 shares of common stock issued and outstanding as of March 4, 2025.
Material Changes and Clinical Updates
The filing reports the announcement of safety results from the final Phase 3 trials for CTx-1301. Key findings include:
- No subjects experienced a serious treatment emergent adverse event (TEAE), a serious TEAE, or a TEAE leading to death.
- No clinically relevant trends in TEAEs overall were observed.
- Pharmacokinetics of the food effect study are under analysis, but medical findings align with previous 25mg dose studies indicating the drug can be taken with or without food.
Outlook, Guidance, and Risks
Management expects a final analysis combining adult and pediatric safety and efficacy data to be announced in mid-2025. This data will be included in the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). The filing notes that the information is furnished under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed clinical data.
- Monitor the mid-2025 timeline for the combined safety and efficacy data announcement.
- Confirm the status of the NDA submission to the FDA following the mid-2025 data release.
- Review the Company's most recent 10-K or 10-Q for financial position, cash runway, and liquidity details not included in this 8-K.